Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Total Liabilities for 3 consecutive years, with $748.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Liabilities rose 20.73% year-over-year to $748.6 million; the TTM figure through Dec 2025 stood at $748.6 million (up 20.73% YoY), while the FY2025 annual figure was $748.6 million, up 27.44% from the prior year.
• Total Liabilities advanced to $748.6 million in Q4 2025 per TLX's latest filing, from $620.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $748.6 million in Q4 2025 and bottomed at $167.3 million in Q4 2023.
• Historically, Total Liabilities has averaged $512.0 million across 3 years, with a median of $620.1 million in 2024.
• Annual changes were most pronounced in 2024 — Total Liabilities soared 270.57% — and 2025, when it advanced 20.73%.
• Telix Pharmaceuticals' Total Liabilities stood at $167.3 million in 2023, then soared by 270.57% to $620.1 million in 2024, then climbed by 20.73% to $748.6 million in 2025.
• Business Quant data shows TLX's Total Liabilities at $748.6 million in Q4 2025, $620.1 million in Q4 2024, and $167.3 million in Q4 2023.